Effectiveness of Erythropoiesis-Stimulating Agent Therapy with Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients. JFM. 2026;9(1):499-507. doi:10.35451/jfm.v9i1.3691